UNITED THERAPEUTICS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 264.3 USD | -0.67% |
|
+0.71% | +20.18% |
Presenter SpeechEun Yang (Analysts)Good morning, everyone. This is Eun Yang, a biotech analyst...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
264.3
USD
Average target price
292.7
USD
Spread / Average Target
+10.77%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.18% | 11.72B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +46.51% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- UTHR Stock
- News United Therapeutics Corporation
- Transcript : United Therapeutics Corporation Presents at 2022 Jefferies Global Healthcare Conference, Jun-09-2022 11